BIOMÉRIEUX |
Market Closed -
Other stock markets
|
After market 19:02:00 | |||
| 110.20 EUR | +0.64% |
|
110.70 | +0.45% |
Summary: bioMérieux
- The company has a good ESG score relative to its sector, according to Refinitiv.
Highlights: bioMérieux
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses: bioMérieux
- The company benefits from high valuations in earnings multiples.
- The company's enterprise value to sales, at 3.27 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings Chart: bioMérieux
Source: Surperformance
ESG chart: bioMérieux
Source: Refinitiv
| Composite Fundamentals | Composite Valuation | Composite Momentum | Capi. ($) | ||
|---|---|---|---|---|---|
| 14.23B | |||||
| 7.61B | |||||
| - | 7.08B | ||||
| 6.04B | |||||
| 3.24B | |||||
| 3.17B | |||||
| - | 2.66B | ||||
| - | 2.39B | ||||
| - | 1.39B | ||||
| Average | 5.31B | ||||
| Weighted average by Cap. |
Investor Rating
Trading Rating
ESG Refinitiv
B+
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- BIM Stock
- Ratings bioMérieux
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition